Relypsa Inc (RLYP) Option Volume Pops Amid Big-Cap Buyout Buzz

Relypsa Inc (NASDAQ:RLYP) options are on fire amid rumors of Merck & Co., Inc. (NYSE:MRK) interest

by Andrea Kramer

Published on Dec 4, 2015 at 12:58 PM
Updated on Dec 4, 2015 at 1:27 PM

Relypsa Inc (NASDAQ:RLYP) has surged 17.2% to $26.20, after StreetInsider sources said Merck & Co., Inc. (NYSE:MRK) is interested in buying the California-based drugmaker. What's more, RLYP options are flying off the shelves, with some traders betting on a surge north of $30 in the next couple of weeks.

Total options volume is running at five times the norm, though RLYP calls are outpacing puts by a margin of 3-to-1. In fact, with more than 6,000 calls across the tape, today's volume is on pace for a 52-week high. Reflecting the growing volatility expectations, RLYP's 30-day at-the-money implied volatility has skyrocketed 36.3% to 135.7% -- just 38 percentage points from an annual high.

Most popular is the December 30 call, which is seemingly attracting new buyers. By purchasing the call at a volume-weighted average price (VWAP) of $1.51, the traders' profit will grow the higher RLYP soars north of $31.51 (strike plus VWAP) by the close on Friday, Dec. 18, when front-month options expire. Delta on the call has nearly doubled overnight, to 0.36 from 0.17, suggesting the odds of an in-the-money finish now stand at 36%.

RLYP hasn't traded atop $30 since before its October implosion, which sent the shares sinking to a record low of $10.26. In fact, the stock's plunge inspired quite a few bears, with short interest surging nearly 60% during the past two reporting periods. These pessimistic positions now account for 20.6% of RLYP's total available float. Against this backdrop, perhaps some of today's out-of-the-money call buyers are short sellers seeking a short-term hedge.

Whatever the motive, today's appetite for long Relypsa Inc's (NASDAQ:RLYP) calls is nothing new. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the biotech has racked up a 10-day call/put volume ratio of 10.58. In other words, traders have bought to open nearly 11 calls for every put during the past two weeks.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.